Joint Meeting of the Nonprescription Drugs Advisory Committee and the Pediatric Advisory Committee; Notice of Meeting, 46091-46092 [E7-16169]

Agencies

• Food and Drug Administration
• DEPARTMENT OF HEALTH AND HUMAN SERVICES

[Federal Register Volume 72, Number 158 (Thursday, August 16, 2007)]
[Notices]
[Pages 46091-46092]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-16169]



[[Page 46091]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2007P-0074]


Joint Meeting of the Nonprescription Drugs Advisory Committee and 
the Pediatric Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committees: Nonprescription Drugs Advisory Committee and 
the Pediatric Advisory Committee.
    General Function of the Committees: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on October 18 and 19, 2007, 
from 8 a.m. to 5 p.m.
    Addresses: Electronic comments should be submitted to https://
www.fda.gov/dockets/ecomments. Select ``2007P-0074--Final Monongraph 
for Cough, Cold, Allergy, Brochodilator, Antiasthmatic Drug Products 
for Over-the-Counter Human Use'' and follow the prompts to submit your 
statement. Written comments should be submitted to the Division of 
Dockets Management (HFA-305), Food and Drug Administration, 5630 
Fishers Lane, Rm. 1061, Rockville, MD 20852, by close of business on 
August 28, 2007.
    Location: The National Labor College, Lane Kirkland Center, 
Solidarity Hall, 10000 New Hampshire Ave., Silver Spring, MD. The phone 
number is 301-431-6400.
    Contact Person: Darrell Lyons, Center for Drug Evaluation and 
Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for 
express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 
301-827-7001, FAX: 301-827-6776, e-mail: darrell.lyons@fda.hhs.gov, or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), codes 3014512541 and 8732310001. Please 
call the Information Line for up-to-date information on this meeting. A 
notice in the Federal Register about last minute modifications that 
impact a previously announced advisory committee meeting cannot always 
be published quickly enough to provide timely notice. Therefore, you 
should always check the agency's Web site and call the appropriate 
advisory committee hot line/phone line to learn about possible 
modifications before coming to the meeting.
    Agenda: The committees will meet in joint session to discuss the 
safety and efficacy of over-the-counter (OTC) cough and cold products 
marketed for pediatric use. A citizen petition was submitted to FDA on 
March 1, 2007, that raised concerns about the safety and efficacy of 
cough and cold products in children under 6 years of age. The petition 
requested among other things that FDA amend the OTC drug monograph for 
Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products 
(CCABADP) in 21 CFR Part 341 to require that labeling for OTC 
antitussive, expectorant, nasal decongestant, antihistamine, and 
combination cough and cold products state that these products have not 
been found to be safe or effective in children under 6 years of age for 
the treatment of cough and cold, and that these products should not be 
used for the treatment of cough and cold in children under 6 years of 
age. In addition, the petitioner requested the agency to notify 
manufacturers of these products whose labeling either uses such terms 
as ``infant'' or ``baby'' or displays images of children under the age 
of 6, that such marketing is not supported by scientific evidence and 
that manufacturers will be subject to enforcement action at any time. 
The petition and additional information can be found at the following 
Web site: https://www.fda.gov/ohrms/dockets/dockets/07p0074/07p0074.htm.
    The committee's discussion will focus on several areas of interest 
which include: The extrapolation of efficacy data from adults to 
children of any age for cough and cold products; the safety profile of 
these products in children; the basis for dosing recommendations in the 
CCABADP monograph and the use of extrapolation of pharmacokinetic data 
to determine appropriate dosing in children; the basis of dosing 
recommendations for various age intervals of less than 2 years, 2 to 5 
years of age, and 6 to 11 years of age; the use of the products in 
children less than 2 years of age; the potential for misuse, 
unintentional overdose, and excessive dosing; the ability of parents or 
caregivers to correctly dose and administer cough and cold products to 
their children; and the potential labeling changes recommended by the 
petitioner and the effects they will have on the use of these products 
in children and the recommendations of health providers.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at https://www.fda.gov/ohrms/dockets/ac/acmenu.htm; click on 
the year 2007 and scroll down to the appropriate advisory committee 
link.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person on or before 
October 3, 2007. Oral presentations from the public will be scheduled 
between approximately 1 p.m. and 3 p.m. on October 18, 2007. Those 
desiring to make formal oral presentations should notify the contact 
person and submit a brief statement of the general nature of the 
evidence or arguments they wish to present, the names and addresses of 
proposed participants, and an indication of the approximate time 
requested to make their presentation on or before September 25, 2007. 
Time allotted for each presentation may be limited. If the number of 
registrants requesting to speak is greater than can be reasonably 
accommodated during the scheduled open public hearing session, FDA may 
conduct a lottery to determine the speakers for the scheduled open 
public hearing session. The contact person will notify interested 
persons regarding their request to speak by September 26, 2007.
    Persons attending FDA's advisory committee meetings are advised 
that the agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Darrell Lyons at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at https://www.fda.gov/oc/advisory/
default.htm for procedures on public conduct during advisory committee 
meetings.

[[Page 46092]]

    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 9, 2007.
Randall W. Lutter,
Deputy Commissioner for Policy.
[FR Doc. E7-16169 Filed 8-15-07; 8:45 am]
BILLING CODE 4160-01-S